Author: Invivyd

Posted Date:

April 9, 2026

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Invivyd

April 9, 2026
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

Invivyd

April 7, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd

April 6, 2026
Invivyd Announces Presentation at the World Vaccine Congress Washington

Invivyd

March 30, 2026
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

Invivyd

March 5, 2026
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

Invivyd

March 5, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd

March 2, 2026
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

Invivyd

March 2, 2026
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies

Invivyd

February 24, 2026
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Invivyd

February 3, 2026